OncBioMune to Present at 18th Annual BIO CEO & Investors Conference

BATON ROUGE, LA--(Marketwired - January 25, 2016) -  OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company will be presenting at the 18^th Annual BIO CEO & Investor Conference being held February 8-9, 2016 at the Waldorf Astoria in New York City. Dr. Jonathan Head, Chief Executive Officer at OncBioMune, will be presenting at 3:30 PM ET on Tuesday, February 9 in the Duke of Windsor room during the conference's Oncology Track. 

The presentation will include a corporate overview that includes the latest data from the ongoing Phase 1 clinical trial of ProscaVax for prostate cancer; information on the Phase 2 trial of ProscaVax planned for the first half of 2016; and other clinical and business developments. The presentation will be webcast and available on the "Investors" section of the OncBioMune website (www.OncBioMune.com) following the live presentation.

Additionally, OncBioMune management will be available for individual meetings with conference attendees. Interested parties can contact OncBioMune to arrange a meeting at: https://oncbiomunepharmaceuticalsinc.partnering.bio.org/inova-business-platform/webclient/#/bio/1300/home?_ga=1.208899035.830712129.1443542113 or by contacting Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune at: akucharchuk@oncbiomune.com.

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax™ is scheduled to commence a Phase 2 clinical study in early 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceutical's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.